According to filings with the U.S. Securities and Exchange Commission, Intelligent Bio Solutions is raising up to $9,978,059.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Intelligent Bio Solutions
Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company dedicated to developing transformative, accurate, and pain-free solutions to improve quality of life. The company specializes in non-invasive drug testing, leveraging innovative technology to detect commonly abused drugs through fingerprint sweat analysis. Their flagship product, the Intelligent Fingerprinting Drug Testing Solution, offers rapid results within ten minutes and is designed for ease of use and portability, identifying potential drug misuse within 16-24 hours before testing. Additionally, Intelligent Bio Solutions offers the SmarTest Sweat Drug Testing Patch, a discreet, wearable device for longer-term drug monitoring over a 7 to 10-day period, ideal for justice and rehabilitation settings. With a recent FDA 510(k) submission in December 2024 and planned entry into the US market in 2025, INBS is strategically positioned to capitalize on the growing drug screening products market.

To learn more about Intelligent Bio Solutions, visit https://ibs.inc/
Intelligent Bio Solutions Linkedin Page: https://www.linkedin.com/company/ibsinc/

Contact:
Spiro Sakiris, Chief Financial Officer
646-790-5756
https://www.linkedin.com/in/spiro-sakiris-39395a7/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.